Positron emission tomography/computed tomography surveillance in patients with lymphoma: A fox hunt?

Haematologica

Volumn 97, Issue 6, 2012, Pages 797-799

  Gallamini, Andrea ^a   Kostakoglu, Lale ^b  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER RELAPSE; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST BENEFIT ANALYSIS; EDITORIAL; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

FEMALE; HODGKIN DISEASE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84862143984     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.063909     Document Type: Editorial

References (23)

1. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J. 2009;15(2):161-3.
2. Seshadri T, Kuruvilla J, Crump M, Keating A. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2008;14(3):259-67.
3. Zinzani PL, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27(11):1781-7.
4. Canellos GP, Horwich A. Management of recurrent Hodgkin's disease. In Hodgkin's disease. Mauch P, Armitage J eds. Lippincott, William & Wilkins, 1999; p. 505-19.
5. Armitage JO, Loberiza FR. Is there a place for routine imaging for patients in complete remission from aggressive lymphoma? Ann Oncol. 2006;17(6):883-4
6. Radford JA, Eardley A, Woodman C, Crowther D. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine test? A review of hospital records. BMJ 1997;314(7077):343-6.
7. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for post therapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: a systematic review. J Nucl Med. 2008;49(1):13-21.
8. Mocikova H, Obrtlikova P, Vackova B, Trneny M. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol. 2010;21(6):1222-7.
9. Lee AI, Zuckerman DS, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission. Cancer 2010;116(16):3835-42.
10. Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol. 2011;90(2):165-71
11. Petrausch U, Samaras P, Veit-Haibach P, Tschopp A, Soyka JD, Knuth A, et al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol. 2010;21(5):1053-7.
12. El-Galaly TC, Mylam KJ, Brown P, Specht L, Christiansen I, Munksgaard L, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica 2012;97(6):931-6.
13. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17(4):1244.
14. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257-60.
15. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly treated patient population. Ann Oncol. 2006;17(6):909-13.
16. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin. Oncol. 2010; 28(27):4184-90.
17. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2002; 20(1):221-30.
18. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991;9(7):1196-203.
19. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-52.
20. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma Blood. 2006;107(1):52-9.
21. Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG-PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50(4):527-33.
22. Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. Cancer. 2003;97(11):2748-59.
23. El-Galaly T, Prakash V, Christiansen I, Madsen J, Johansen P, Boegsted M, et al. Efficacy of routine surveillance with positron emission tomography/ computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma. 2011;52(4):597-603.